HEALTH OF WOMAN. 2020.9-10(155-156): 83-90; doi 10.15574/HW.2020.155-156.83
Syusyuka V. G., Kolokot N. G., Belenichev I. F.
Zaporizhia State Medical University

The objective: estimate efficiency and influence of complex, cytoprotective therapy of pregnant women with fetal growth delay on biochemical indexes and results of delivery.
Materials and methods. 93 women with monocyesis at term of 28-34 gestation weeks took part in the research. Group І includes 30 pregnant women with fetal growth delay (FGD). The pregnant women of the present group were prescribed with complex, cytoprotective therapy. It includes prescription of thiotriazolin in complex with L-arginine and diosmin. Group ІІ is presented by 33 pregnant women with FGD whose management of pregnancy and delivery is provided by valid orders of Ministry of Healthcare of Ukraine. Group ІІІ (the control one) consists of 30 pregnant women without FGD.
Research of protein oxidative modification (POM) markers and level of stable nitrogen oxide metabolites (NO) were estimated in blood serum with spectrophotometric method. Reduced glutathione (GSH) was determined with calculation of its level according to the calibration curve.
Results. Primary estimation of their content showed statistically valid (p < 0.05) lower GSH and NO in comparison of indexes of pregnant women without FGD (ІІІ group) with indexes of pregnant women with FGD (both І and ІІ groups). This fact indicates decrease of antioxidant protection and deficit of the main vessel dilator in the present group.
Further estimation of biochemical indexes in dynamics of pregnancy permitted to determine considerable progress of imbalance between oxidants and antioxidants and absence of significant changes of NO level among pregnant women of II group. In pregnant women of I group who got the proposed complex cytoprotective therapy, on contrary, statistically valid (p < 0.05) decrease of POM indexes together with increase of GSH and NO level that indicates its positive influence were found.
By means of analysis of special features of the pregnancy course in research group there was stated that the rate of habitual pregnancy non-carrying (HPN) in group II made 39.4% and considerably exceeded relevant indexes of І (20.0%) and ІІІ (16.7%) groups. Hypertensive disorders during pregnancy and labour are diagnosed only in pregnant women of І (6.7%) and ІІ (9.1%) groups. Average index of giving birth in І and ІІІ groups made 38.5±0.6 weeks and 39.4 ± 0.5 weeks correspondingly and in group ІІ it was lower 37.2±0.6 weeks. Index of preterm delivery (PD) rate in І group made 3.3% and was 6 times lower than appropriate index of ІІ group (21.2%). PD rate was absent in ІІІ group. Rate of the fetus distress in ІІ group (18.2%) was 2.7 times higher than the relevant index of І group (6.7%) and in ІІІ group it made 3.3%. Condition of newborns in research groups was estimated under Apgar scale. Both at the 1-st and 5-th minute the general index under appropriate scale was statistically valid (p < 0.05) and lower than in ІІ group as compared to indexes of І and ІІІ groups. During description of perinatal complications there was stated considerable percentage of neonatal encephalopathy and jaundice in ІІ group, namely 33.3% and 36.4% correspondingly. In І group their rate made 10.0% and 3.3%, correspondingly.
In structure of perinatal pathology prematurity was in 21.2% of newborns of ІІ group that is 6 times higher than appropriate index of І group (3.3%). Mentioned complications were not determined in ІІІ group. In calculation under weight and height parameters of newborns the rate of FGD in ІІ group was the highest and made 88.6%. Mentioned index in І and ІІІ groups made 60.0% and 10.0%, correspondingly.
Conclusion. The proposed complex cytoprotective therapy including combined use of thiotriazolin, L-arginine and diosmin (that considerably increases anti-ischemic, antioxidant and endothelium protective action of complex therapy) in women with fetal growth delay has the positive effect on oxidative-reductive hemeostasis and thiol-disulfide balance of mother-placenta-fetus system.
Obstetric and perinatal results of delivery in the present group of pregnant women are characterized by statistically valid (р < 0.05) prevalence of estimation indexes under Apgar scale and correspondingly processes of adaptation as well as results of anthropomorphic measurements of newborns, their weight and height parameters and lower rate of neonatal encephalopathy and delivery of premature babies.
Keywords: pregnancy, fetus growth inhibition, protein oxidative modification, antioxidant defense system, oxidative stress, obstetric and perinatal complications, cytoprotective therapy.

REFERENCES

1. Chekman IS, Belenichev IF, Gorchakova NA i dr. 2014. Antioksidanty: kliniko-farmakologicheskiy aspekt. Ukr. med. chasopis 1(99):22–28.

2. Basystyi OV. 2016. Dysbalans u systemi L-arhinin – oksyd azotu u patohenezi akusherskykh uskladnen i zatrymky rostu ploda (Ohliad literatury). Zdorove zhenshchyny 5(111):43–47. https://doi.org/10.15574/HW.2016.111.43

3. Lahno IV, Korovay SV, Dudko VL, Neelova OV. 2009. Vyibor metoda lecheniya hronicheskoi venoznoi nedostatochnosti vo vremya beremennosti. Zdorove zhenschiny 2:73–76.

4. Hopchuk OM. 2017. Platsentarna dysfunktsiia u vahitnyh iz suputnoiu patologiieiu sertsevo-sudynnoi systemy. Zdorove zhenshchyny 7(123):88–92.

5. Hromova AM, Berezhna VA. 2018. Etiologichni ta patohenetychni aspekty zatrymky vnutrishnoutrobnoho rozvytku ploda. Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii «Aktualni problemy suchasnoi medytsyny» 18;Vyp. 3 (63):301–307.

6. Likhachov VK, Taranovska OO, Semeniuk LM, Yaremchuk LV. 2014. Dynamika zmin oksydu azotu ta rozvytku hestatsiinoi endoteliopatii pry preeklampsii. Visnyk problem biologii i medytsyny 3 (3):146–150.

7. Chekman IS, Bielenichev IF, Nahorna OO ta in. 2016. Doklinichne vyvchennia spetsyfichnoi aktyvnosti potentsiinykh likarskykh zasobiv pervynnoi ta vtorynnoi neiroprotektsii: metod. rekomendatsii. K, TOV «Vydavnytstvo «Iuston»:80.

8. Vdovychenko YuP, Tanko OP, Samoilova MV, Sharashydze KZ. 2017. Zatrymka rostu ploda: kliniko-patohenetychni skladovi ta zasoby poperedzhennia. Adaptatsiia do mizhnarodnyh klinichnyh ustanov. K:43.

9. Ihtiyarova GA, Suleymanova GS. 2020. Primenenie preparata Flebodia 600 v lechenii fetoplatsentarnoy nedostatochnosti u beremennyih s varikoznoy boleznyu. «Liky – liudyni. Suchasni problemy farmakoterapii i pryznachennia likarskyh zasobiv»: materialy IV Mizhnar. nauk.-prakt. konf. (12–13 bereznia 2020 roku). u 2-kh t. Kh, NFaU. 1:208–210.

10. Katkova NYu, Panova TV. 2006. Effektivnost angioprotektorov pri lechenii beremennyih s platsentarnoy nedostatochnostyu. Consilium Medicum. 8;2:28–30.

11. Klyicheva OI. 2016. Morfofunktsionalnyie osobennosti sostoyaniya fetoplatsentarnogo kompleksa u zhenschin s sindromom zaderzhki razvitiya ploda. Sovremennyiy nauchnyiy vestnik 10;1:54–58.

12. Klyicheva OI, Huraseva AB. 2017. Sravnitelnyiy analiz farmakologicheskoy effektivnosti angioprotektornyih preparatov v terapii sindroma zaderzhki rosta ploda. Kurskiy nauchno-prakticheskiy vestnik «Chelovek i ego zdorove» 3:4348.

13. KovalYov EV, Zanko YuV. 2016. Vliyanie terapii platsentarnoy nedostatochnosti i zaderzhki rosta ploda na sostoyanie novorozhdennyh. Fundamentalnaya i klinicheskaya meditsina 1;2:38–45.

14. KovalYov EV, Zanko YuV, Yarotskaya NN. 2014. Otsenka pokazateley perekisnogo okisleniya lipidov, antioksidantnoy sistemy krovi i sostoyaniya endoteliya u patsientov pri formirovanii zaderzhki rosta ploda. Vestnik VGMU 13;5:74–80.

15. Potapov VA, Syusyuka VG, Shapran NF, Nechuhaeva IA, Serbolov DV. Kompleksnyiy podhod k lecheniyu i reabilitatsii beremennyih s venoznoy patologiey. Materialy kongressa «Slavyanskii venoznyi forum», Vitebsk 28–29 maya, 2015: 54–55.

16. Konkov DG, Galich SR, Belkaniya GS. 2013. Klinicheskoe znachenie gestatsionnoy endoteliopatii. Z turbotoyu pro zhinku 2:64–67.